&lt;p&gt;Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review&lt;/p&gt;

Ghasemiyeh, Parisa; Borhani‐Haghighi, Afshin; Karimzadeh, Iman; Mohammadi-Samani, Soliman; Vazin, Afsaneh; Safari, Anahid; Qureshi, Adnan I

doi:10.2147/tcrm.s259152

Cited by 52 publications

(50 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, as we deal with critically ill patients with COVID-19 with underlying co-morbidities, clinicians need to be careful about co-administering drugs with remdesivir and be updated regularly as new data emerge [ 42 ]. More DDIs are expected for corticosteroids [ 43 ] and direct oral anticoagulants often used in place of enoxaparin [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Drug–Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy

et al. 2020

View full text Add to dashboard Cite

Background Patients hospitalised with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2; coronavirus 2019 disease (COVID-19)] infection are frequently older with co-morbidities and receiving polypharmacy, all of which are known risk factors for drug–drug interactions (DDIs). The pharmacological burden may be further aggravated by the addition of treatments for COVID-19. Objective The aim of this study was to assess the risk of potential DDIs upon admission and during hospitalisation in patients with COVID-19 treated at our hospital. Methods We retrospectively analysed 502 patients with COVID-19 (mean age 61 ± 16 years, range 15–99) treated at our hospital with a proven diagnosis of SARS-CoV-2 infection hospitalised between 21 February and 30 April 2020 and treated with at least two drugs. Results Overall, 68% of our patients with COVID-19 were exposed to at least one potential DDI, and 55% were exposed to at least one potentially severe DDI. The proportion of patients experiencing potentially severe DDIs increased from 22% upon admission to 80% during hospitalisation. Furosemide, amiodarone and quetiapine were the main drivers of potentially severe DDIs upon admission, and hydroxychloroquine and particularly lopinavir/ritonavir were the main drivers during hospitalisation. The majority of potentially severe DDIs carried an increased risk of cardiotoxicity. No potentially severe DDIs were identified in relation to tocilizumab and remdesivir. Conclusions Among hospitalised patients with COVID-19, concomitant treatment with lopinavir/ritonavir and hydroxychloroquine led to a dramatic increase in the number of potentially severe DDIs. Given the high risk of cardiotoxicity and the scant and conflicting data concerning their efficacy in treating SARS-CoV-2 infection, the use of lopinavir/ritonavir and hydroxychloroquine in patients with COVID-19 with polypharmacy needs to be carefully considered.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug–Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…23 It has been documented that favipiravir manifests a good safety profile concerning the total and submit your manuscript | www.dovepress.com severe ADEs, and it might rarely induce drug-related psychotic symptoms. 28 Due to the limited availability of the data, robust multicentric randomized controlled trials are warranted to establish the safety and efficacy of favipiravir against SARS-CoV-2. In the trials conducted until now, diarrhea, hyperuricemia, and liver toxicity are the typical adverse reactions of favipiravir.…”

Section: Introductionmentioning

confidence: 99%

<p>Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database</p>

Kaur¹,

Charan²,

Dutta³

et al. 2020

IDR

View full text Add to dashboard Cite

Background COVID-19 caused by SARS-CoV-2 virus emerged as an unprecedented challenge to discover effective drugs for its prevention and cure. Hyperinflammation-induced lung damage is one of the poor prognostic indicators causing a higher rate of morbidity and mortality of COVID-19 patients. Favipiravir, an antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety. Thus, the present study was undertaken to evaluate the adverse drug events (ADEs) reported in the WHO pharmacovigilance database. Methods This study analyzed all suspected ADEs related to favipiravir reported from 2015. The reports were analyzed based on age, gender, and seriousness of ADEs at the System Organ Classification (SOC) level and the individual Preferred Term (PT) level. Results This study is based on 194 ADEs reported from 93 patients. Most frequent ADEs suspected to be caused by the favipiravir included increased hepatic enzymes, nausea and vomiting, tachycardia, and diarrhea. Severe and fatal ADEs occurred more frequently in men and those over the age of 64 years. Blood and lymphatic disorders, cardiac disorders, hepatobiliary disorders, injury poisoning, and procedural complications were more common manifestations of severe ADEs. Conclusion This study revealed that favipiravir appears to be a relatively safe drug. An undiscovered anti-inflammatory activity of favipiravir may explain the improvement in critically ill patients and reduce inflammatory markers. Currently, the data is based on very few patients. A more detailed assessment of the uncommon ADEs needs to be analyzed when more information will be available.

show abstract

“…The most frequently used antiviral drugs at the beginning of the pandemic (i.e. chloroquine and hydroxychloroquine) later demonstrated neurological side effects, such as seizures and peripheral neuropathy [ 19 ].…”

Section: Pathophysiology Of Nervous System Involvementmentioning

confidence: 99%

Insights into neurological dysfunction of critically ill COVID-19 patients

Deana

Verriello

Pauletto

et al. 2021

Trends in Anaesthesia and Critical Care

View full text Add to dashboard Cite

Novel coronavirus spread rapidly around the world infecting millions of people. It was thus declared a pandemic. This new virus damages the lungs. In the most severe cases, it leads to acute respiratory failure that requires intensive care treatment. However, many clinical reports have listed different neurological symptoms, leading to increased interest in the neurological involvement of COVID-19. Various pathophysiological mechanisms have been proposed to explain these neurological aspects. Direct viral invasion of the nervous system, systemic cytokine storm and severe hypoxemia are key factors in the development of symptoms. Critically ill patients present several additional risk factors for nervous system damage. Reasons for these include deep sedation and extended muscular paralysis, bed rest for several days, and the inability to receive proper physical rehabilitation. After ICU treatment, COVID-19 patients generally require an extensive rehabilitation program. However, distancing restrictions mean that in many cases physiotherapists are unable to enter ICUs, delaying the process of rehabilitation. The role of telemedicine should be considered as an adjunctive tool in the rehabilitation of critically ill COVID-19 patients.

show abstract

<p>Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review</p>

Cited by 52 publications

References 76 publications

Drug–Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy

Drug–Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy

<p>Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database</p>

Insights into neurological dysfunction of critically ill COVID-19 patients

Contact Info

Product

Resources

About